The Symetis ACURATE TA valve demonstrates high procedural success and favorable short-term survival in high-risk patients with severe aortic stenosis undergoing transapical TAVI.
Answers are grounded in this paper and cite their sources.
Supports short-term safety of ACURATE TA in high-risk aortic stenosis; leaves open need for randomized comparisons.
Transapical transcatheter aortic valve implantation (TA-TAVI) is the recognized first choice surgical TAVI access. Expansion of this well-established treatment modality with subsequent broader patient inclusion has accelerated development of second-generation TA-TAVI devices. The Swiss ACURATE TA Symetis valve allows for excellent anatomical positioning, resulting in a very low incidence of paravalvular leaks. The self-expanding stent features an hourglass shape to wedge the native aortic valve annulus. A specially designed delivery system facilitates controlled release aided by tactile operator feedback. The ACURATE TA valve made of three native porcine non-coronary leaflets has received CE approval in September 2011. Since then, this valve is the third most frequently implanted TAVI device with over 1200 implants in Europe and South America. Results from the Symetis ACURATE TA™ Valve Implantation ('SAVI') Registry showed a procedural success rate of 98.0% and a survival rate of 93.2% at 30 days. This presentation provides technical considerations and detailed procedural aspects of device implantation.
No takes yet. Share an insight, caveat, or question.
Huber et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: